Cargando…
DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
Heart failure (HF) continues to be a major global health problem with a notable impact in terms of morbidity and mortality and so, in consequence, with a large unmet necessity for new therapies. The inhibition of sodium–glucose cotransporter 2 (SGLT2) causes glycosuria and natriuresis, leading to re...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioExcel Publishing Ltd
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051244/ https://www.ncbi.nlm.nih.gov/pubmed/32165892 http://dx.doi.org/10.7573/dic.2019-11-3 |